MX2021004387A - Composiciones y metodos para el tratamiento de sindrome vascular de ehlers danlos y trastornos asociados. - Google Patents
Composiciones y metodos para el tratamiento de sindrome vascular de ehlers danlos y trastornos asociados.Info
- Publication number
- MX2021004387A MX2021004387A MX2021004387A MX2021004387A MX2021004387A MX 2021004387 A MX2021004387 A MX 2021004387A MX 2021004387 A MX2021004387 A MX 2021004387A MX 2021004387 A MX2021004387 A MX 2021004387A MX 2021004387 A MX2021004387 A MX 2021004387A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- associated disorders
- treating vascular
- danlos syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746524P | 2018-10-16 | 2018-10-16 | |
| US201862747587P | 2018-10-18 | 2018-10-18 | |
| US201962838049P | 2019-04-24 | 2019-04-24 | |
| PCT/US2019/056616 WO2020081741A2 (en) | 2018-10-16 | 2019-10-16 | Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004387A true MX2021004387A (es) | 2021-08-19 |
Family
ID=70284358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004387A MX2021004387A (es) | 2018-10-16 | 2019-10-16 | Composiciones y metodos para el tratamiento de sindrome vascular de ehlers danlos y trastornos asociados. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11938135B2 (enExample) |
| EP (2) | EP4268822A3 (enExample) |
| JP (3) | JP7678748B2 (enExample) |
| KR (1) | KR20210094532A (enExample) |
| CN (2) | CN121197400A (enExample) |
| AU (2) | AU2019359872B2 (enExample) |
| BR (1) | BR112021007237A2 (enExample) |
| CA (1) | CA3116321A1 (enExample) |
| DK (1) | DK3866799T3 (enExample) |
| ES (1) | ES2973130T3 (enExample) |
| FI (1) | FI3866799T3 (enExample) |
| IL (1) | IL281623A (enExample) |
| MX (1) | MX2021004387A (enExample) |
| PL (1) | PL3866799T3 (enExample) |
| PT (1) | PT3866799T (enExample) |
| WO (1) | WO2020081741A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121197400A (zh) | 2018-10-16 | 2025-12-26 | 约翰斯·霍普金斯大学 | 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法 |
| WO2021202643A1 (en) * | 2020-03-31 | 2021-10-07 | The Regents Of The University Of California | Compositions and methods for treating dysregulated wound healing |
| EP4208203A4 (en) * | 2020-09-04 | 2024-09-04 | The Johns Hopkins University | TREATMENT OF VASCULAR EHLERS-DANLOS SYNDROME AND ASSOCIATED SYNDROMES |
| WO2023150702A2 (en) * | 2022-02-03 | 2023-08-10 | The Johns Hopkins University | Compositions and methods for treatment of connective tissue disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| DE102004019413A1 (de) | 2004-04-19 | 2005-11-24 | Phenos Gmbh | Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten |
| WO2013170147A1 (en) * | 2012-05-11 | 2013-11-14 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| AU2016232705C1 (en) * | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| BR112018008882A8 (pt) | 2015-11-03 | 2019-02-26 | Univ Texas | método para tratar um distúrbio proliferativo e produto farmacêutico |
| WO2018160987A1 (en) | 2017-03-02 | 2018-09-07 | The Johns Hopkins University | Map kinase pathway targets for the treatment of marfan syndrome |
| CN121197400A (zh) | 2018-10-16 | 2025-12-26 | 约翰斯·霍普金斯大学 | 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法 |
-
2019
- 2019-10-16 CN CN202511337632.1A patent/CN121197400A/zh active Pending
- 2019-10-16 DK DK19872573.1T patent/DK3866799T3/da active
- 2019-10-16 BR BR112021007237-3A patent/BR112021007237A2/pt not_active Application Discontinuation
- 2019-10-16 EP EP23191111.6A patent/EP4268822A3/en active Pending
- 2019-10-16 CA CA3116321A patent/CA3116321A1/en active Pending
- 2019-10-16 EP EP19872573.1A patent/EP3866799B1/en active Active
- 2019-10-16 CN CN201980067015.0A patent/CN113194946B/zh active Active
- 2019-10-16 PT PT198725731T patent/PT3866799T/pt unknown
- 2019-10-16 MX MX2021004387A patent/MX2021004387A/es unknown
- 2019-10-16 US US17/286,414 patent/US11938135B2/en active Active
- 2019-10-16 FI FIEP19872573.1T patent/FI3866799T3/fi active
- 2019-10-16 KR KR1020217014599A patent/KR20210094532A/ko active Pending
- 2019-10-16 ES ES19872573T patent/ES2973130T3/es active Active
- 2019-10-16 PL PL19872573.1T patent/PL3866799T3/pl unknown
- 2019-10-16 JP JP2021520923A patent/JP7678748B2/ja active Active
- 2019-10-16 WO PCT/US2019/056616 patent/WO2020081741A2/en not_active Ceased
- 2019-10-16 AU AU2019359872A patent/AU2019359872B2/en active Active
-
2021
- 2021-03-18 IL IL281623A patent/IL281623A/en unknown
-
2024
- 2024-02-07 US US18/435,769 patent/US20240408091A1/en active Pending
- 2024-03-04 JP JP2024031893A patent/JP2024063161A/ja active Pending
-
2025
- 2025-01-16 AU AU2025200315A patent/AU2025200315A1/en active Pending
- 2025-05-02 JP JP2025076487A patent/JP2025118759A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7678748B2 (ja) | 2025-05-16 |
| KR20210094532A (ko) | 2021-07-29 |
| CN121197400A (zh) | 2025-12-26 |
| AU2025200315A1 (en) | 2025-02-13 |
| JP2025118759A (ja) | 2025-08-13 |
| DK3866799T3 (da) | 2024-02-05 |
| PT3866799T (pt) | 2024-03-06 |
| WO2020081741A3 (en) | 2020-05-22 |
| BR112021007237A2 (pt) | 2021-08-10 |
| US20210386740A1 (en) | 2021-12-16 |
| IL281623A (en) | 2021-05-31 |
| EP3866799B1 (en) | 2023-12-06 |
| WO2020081741A2 (en) | 2020-04-23 |
| AU2019359872A1 (en) | 2021-05-27 |
| CN113194946A (zh) | 2021-07-30 |
| EP3866799A4 (en) | 2022-07-27 |
| CN113194946B (zh) | 2025-10-14 |
| FI3866799T3 (fi) | 2024-02-29 |
| ES2973130T3 (es) | 2024-06-18 |
| US20240408091A1 (en) | 2024-12-12 |
| EP3866799A2 (en) | 2021-08-25 |
| JP2024063161A (ja) | 2024-05-10 |
| EP4268822A3 (en) | 2024-01-03 |
| JP2022504990A (ja) | 2022-01-13 |
| PL3866799T3 (pl) | 2024-04-29 |
| AU2019359872B2 (en) | 2024-10-17 |
| CA3116321A1 (en) | 2020-04-23 |
| EP4268822A2 (en) | 2023-11-01 |
| US11938135B2 (en) | 2024-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
| PH12022550165A1 (en) | Interleukin-2 agents and uses thereof | |
| PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| SA518390944B1 (ar) | أجسام مضادة لمثبط مسار عامل نسيج واستخداماتها | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| MX2018006632A (es) | Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4). | |
| MX2018004947A (es) | Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados. | |
| EA201990257A1 (ru) | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением | |
| WO2020081741A3 (en) | Compositions and methods for treating vascular ehlers danlos syndrome and associated disorders | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| EP4327876A3 (en) | Immunogenic compositions | |
| MX2020007555A (es) | Anticuerpos potenciadores del factor h y usos de los mismos. | |
| EP4378535A3 (en) | Antibiotic formulations for lower back pain | |
| PH12019502694A1 (en) | Anti-trkb antibodies | |
| EP3893785A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT OF WOUNDS | |
| MX2020000611A (es) | Composiciones y metodos para tratar trastornos relacionados con el estres. | |
| WO2020021480A3 (en) | Compositions and methods for treating the eye | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| MX390865B (es) | Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand | |
| ZA202006216B (en) | Antibodies targeting glycoprotein vi | |
| AU2018258117A1 (en) | Compositions and method for treating depression | |
| PH12021552499A1 (en) | Methods for the treatment of beta-thalassemia | |
| MY191993A (en) | Use of isolated fractions of mastic gum for treating optic neuropathy |